<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04877639</url>
  </required_header>
  <id_info>
    <org_study_id>XM Song</org_study_id>
    <nct_id>NCT04877639</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Esmketamine Versus Dexmedetomidine</brief_title>
  <official_title>A Comparative Study on the Safety and Efficacy of Esmketamine Versus Dexmedetomidine During Drug Induced Sleep Endoscopy in Children With Positional Obstructive Sleep Apnea: A Consort-prospective, Randomized, Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongnan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongnan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparative study on the safety and efficacy of esmketamine versus Dexmedetomidine during&#xD;
      drug induced sleep endoscopy in children with positional obstructive sleep apnea: A&#xD;
      consort-prospective, randomized, controlled clinical trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: Eighty ASA Ⅰ - Ⅱ patients aged 3-13 years underwent elective surgery under general&#xD;
      anesthesia. No serious cardiovascular disease, no liver and kidney dysfunction, no central&#xD;
      nervous system disease and mental disease. Patients undergoing tonsillectomy under general&#xD;
      anesthesia were selected as the research objects.&#xD;
&#xD;
      80 patients were randomly divided into dexmedetomidine group D (n = 40) and ketamine Group K&#xD;
      (n = 40). Both groups were given midazolam 0.2mg/kg intravenously&#xD;
&#xD;
      Group K: induction: intravenous injection of 1.0mg/kg esmketamine, nasal endoscopy started 3&#xD;
      minutes later, maintained 1.0mg/kg/h esmketamine;&#xD;
&#xD;
      Group D: induction: Dexmedetomidine 1 μ G / kg at least 10 min after intravenous injection +&#xD;
      maintain 1 μ After 5 minutes of intravenous injection of dexmedetomidine 1 ug / kg,&#xD;
      sufentanil 0.05 mg / kg was given.&#xD;
&#xD;
      Propofol 0.5 mg · kg-1 was injected intravenously when the patient had body movement&#xD;
&#xD;
      Heart rate (HR), mean arterial pressure (map), electrocardiogram (ECG), respiratory rate&#xD;
      (RR), pulse oxygen saturation (%, SpO2) and BIS were recorded before (T1), during (T2), after&#xD;
      (T3), 1 min after tracheal intubation (T4), 1 min after extubation (T5) and 30 min after&#xD;
      extubation (T6).&#xD;
&#xD;
      3.2 onset and maintenance time: the time from administration to endoscopic examination (min);&#xD;
      Recovery time (min)&#xD;
&#xD;
      3.3 observation and treatment of adverse reactions during and after dis&#xD;
&#xD;
      3.4 observe the sedation score of the two groups during the dis phase and the awake score 30&#xD;
      minutes after waking up&#xD;
&#xD;
      Objective To observe the application of dexmedetomidine and esmketamine in drug-induced sleep&#xD;
      nasal endoscopy, and to explore the best medication scheme, so as to better guide clinical&#xD;
      medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset time, Vital signs</measure>
    <time_frame>1 year</time_frame>
    <description>Time from administration to operation;Heart rate, blood pressure and body movement during operation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Osa Syndrome</condition>
  <arm_group>
    <arm_group_label>Esmketamine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous injection of 1.0mg/kg esmketamine was given, and nasal endoscopy was started 3 minutes later to maintain 1.0mg/kg/h esmketamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine 1 μg/ kg at least 10 min after intravenous injection + maintain 1 μ After intravenous injection of dexmedetomidine 1 ug / kg, sufentanil 0.05 mg / kg was given 5 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmketamine,Dexmedetomidine</intervention_name>
    <description>Two different drugs were given to observe which of the two drugs was more suitable for DISE detection</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_label>Esmketamine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eighty ASA Ⅰ - Ⅱ patients aged 3-13 years underwent elective surgery under general&#xD;
             anesthesia. No serious cardiovascular disease, no liver and kidney dysfunction, no&#xD;
             central nervous system disease and mental disease. Patients undergoing tonsillectomy&#xD;
             under general anesthesia were selected as the research objects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA grade III and above, abnormal heart, lung, liver and kidney function before&#xD;
             operation; There were central nervous system diseases and mental diseases,&#xD;
             preoperative allergy to anesthetics (dexmedetomidine, esmketamine), family history of&#xD;
             malignant high fever, tracheostomy and other artificial airway.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuanzhen Zhang, professor</last_name>
    <role>Study Chair</role>
    <affiliation>Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuemin Song, professor</last_name>
    <phone>18986073715</phone>
    <email>xueminsong@whu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aming Sang, doctor</last_name>
    <phone>15271945604</phone>
    <email>775661547@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongnan Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuemin Song, professor</last_name>
      <phone>18986073715</phone>
      <email>xueminsong@whu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Aming Sang, doctor</last_name>
      <phone>15271945604</phone>
      <email>775661547@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongnan Hospital</investigator_affiliation>
    <investigator_full_name>Xuemin Song</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <keyword>pediatrics ;Osa Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

